New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 5, 2014
06:31 EDTKPTIKaryopharm reports FY13 EPS ($5.59), may not compare to consensus ($2.93)
Net loss includes stock-based compensation expense of $3.8M and $653,000 for the years ended December 31, 2013 and 2012, respectively.
News For KPTI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 23, 2015
11:11 EDTKPTIKaryopharm management to meet with Maxim
Subscribe for More Information
April 13, 2015
08:43 EDTKPTIKaryopharm granted U.S. composition-of-matter patent for selinexor
Karyopharm Therapeutics announced the issuance of U.S. Patent No. 8,999,996 entitled "Hydrazide Containing Nuclear Transport Modulators and Uses Thereof." This patent, which will expire in 2032 absent any patent term extensions, covers the composition-of-matter of Karyopharm's lead product candidate, selinexor, a first-in-class, oral SINE compound, as well as certain other compositions and related methods. Selinexor is being evaluated in multiple registration-directed and other later stage trials in patients with relapsed and/or refractory hematological and solid tumor malignancies.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use